Combination immunotherapy for hepatocellular carcinoma

肝细胞癌 医学 免疫疗法 肿瘤科 内科学 癌症研究 癌症
作者
Lorenza Rimassa,Richard S. Finn,Bruno Sangro
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:79 (2): 506-515 被引量:181
标识
DOI:10.1016/j.jhep.2023.03.003
摘要

Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20%, mostly without a significant overall survival (OS) benefit. Furthermore, approximately 30% of HCC exhibits intrinsic resistance to ICIs. In the absence of predictive biomarkers to identify patients likely to benefit most from immunotherapy, research has moved to exploring combinations with potential activity in broader patient populations. Basket trials, including cohorts of patients with HCC, and early phase studies tested the combination of ICIs with anti-angiogenic agents as well as the combination of two different ICIs. The promising results that were achieved provided the rationale for the following phase III trials, which tested the combination of anti-PD-1/PD-L1 antibodies with bevacizumab, or tyrosine kinase inhibitors, or anti-CTLA-4 antibodies. Positive results from the IMbrave150 trial led to the practice-changing approval of atezolizumab-bevacizumab, the first regimen to demonstrate improved survival in the front-line setting since the approval of sorafenib. More recently, the HIMALAYA trial demonstrated the superiority of durvalumab-tremelimumab (STRIDE regimen) over sorafenib, establishing a new first-line option. In contrast, inconsistent results have been achieved with combinations of ICIs and tyrosine kinase inhibitors, with only one phase III trial showing an OS benefit. The rapid evolution of the therapeutic landscape for patients with advanced HCC has left many unanswered questions that will need to be addressed by future research. These include the choice and sequencing of treatments, identification of biomarkers, combinations with locoregional therapies, and development of new immunotherapy agents. This review summarises the scientific rationale and available clinical data for combination immunotherapy in advanced HCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
飞云完成签到 ,获得积分10
刚刚
满天星辰独览完成签到 ,获得积分10
刚刚
九天完成签到 ,获得积分10
1秒前
Bin_Liu发布了新的文献求助10
1秒前
feiyang完成签到 ,获得积分10
2秒前
超帅无色发布了新的文献求助10
2秒前
QCB完成签到 ,获得积分10
4秒前
爱笑半雪完成签到,获得积分10
5秒前
CipherSage应助知犯何逆采纳,获得10
6秒前
淡淡月饼完成签到,获得积分10
10秒前
10秒前
超帅无色完成签到,获得积分20
11秒前
snow完成签到 ,获得积分10
12秒前
15秒前
dream完成签到 ,获得积分10
17秒前
唐唐发布了新的文献求助10
17秒前
史克珍香完成签到 ,获得积分10
23秒前
晓风完成签到,获得积分10
26秒前
CR完成签到 ,获得积分10
27秒前
mammer应助超帅无色采纳,获得10
28秒前
科研通AI2S应助科研通管家采纳,获得10
28秒前
所所应助科研通管家采纳,获得10
29秒前
Owen应助科研通管家采纳,获得10
29秒前
29秒前
lilylwy完成签到 ,获得积分0
29秒前
li完成签到 ,获得积分10
29秒前
可爱的函函应助唐唐采纳,获得10
34秒前
小石头完成签到,获得积分10
36秒前
量子星尘发布了新的文献求助10
40秒前
xiaoxiaoxingchen完成签到 ,获得积分10
40秒前
laohu完成签到,获得积分10
41秒前
风格完成签到,获得积分10
41秒前
大橙子发布了新的文献求助150
43秒前
八点必起完成签到,获得积分10
44秒前
sduweiyu完成签到 ,获得积分10
45秒前
hyf完成签到 ,获得积分10
46秒前
aldehyde应助芊芊要发SCI采纳,获得10
47秒前
Twinkle完成签到,获得积分10
49秒前
Eureka完成签到,获得积分10
51秒前
55秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022